To test the hypothesis that anti-DEspR mAb therapy attenuates neutrophil-mediated progression of post-sICH secondary brain injury to ICH-related death, we tested in vivo preclinical efficacy of our murine prototype anti-DEspR monoclonal antibody (mAb), 10a3, while observing for potential adverse effects after acute sICH presentation to determine single-dose effects on progression to early-mortality in the hsICH-rat model14,15; and in the pre-ICH stage to assess multi-dose effects on potential infection risk and adverse events in the presence of ongoing sICH pathogenic progression. The gene discussed is FBXW7-AS1; the disease is infection.